Cardiovascular morbidity and dyslipidemia in chronic kidney disease: a cross-sectional study

Suresh K., Charan Neeradi, Moneshaa S. S.


Background: CKD is a risk factor for CVD and dyslipidemia is an important co-morbidity associated with both. CKD can lead to variations in lipid profile which can lead to atherosclerosis and thereby increase the risk for CVD.

Objective was to analyse the clinical and diagnostic cardiovascular features of CKD patients and the associated variations in their lipid profile.

Methods: This prospective study was conducted from May 2015 to May 2017 among 100 patients attending to Medicine department with documented biochemical and sonographic evidence of chronic kidney disease. The included participants were subjected to routine blood investigations including lipid profile and cardiovascular evaluation which included electrocardiography (ECG), chest X-ray and M-mode 2-Dimensional echocardiography. Data was recorded in a proforma and the results were analysed statistically.

Results: The study included 100 patients with chronic kidney disease, majority (n=42, 42%) of them belonging to the 40-50 years age group. There was similar (p=0.78) representation of males and females in the study. Significantly (p=0.02) higher number (n=58) of alcoholics were present among the CKD patients. Significantly (p=0.04) higher proportion of patients with CKD had high TG (36%) and low HDL (30%) levels. Majority (58%) had CVD morbidity and Left ventricular hypertrophy was a characteristic feature in majority (n=15%) of the CKD patients as evaluated by ECG and ECHO.

Conclusions: The study documented the association of CVD and dyslipidemia with CKD. It also revealed ECG and ECHO changes in CKD patients which can be useful predictors in determining the progression of the CVD complications in CKD.


Chronic Kidney disease, Cardio-vascular disease, Dyslipidemia

Full Text:



Anand S, Shivashankar R, Ali MK, Kondal D, Binukumar B, Montez-Rath ME, et al. Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. Kidney international. 2015;88(1):178-85.

Kidney Disease: Improving Global Outcomes Work Group T. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international Supplement. 2012;2013(3):1-150.

Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Ame Soci Nephrol. 1999;10(7):1606-15.

Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, et al. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res. 2009;50(12):2524-31.

Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European Heart J. 2007;28(19):2375-414.

Schäbitz WR, Reinecke H. Chronic kidney disease and alcohol consumption: are Asians at particular risk for hemorrhagic stroke?. 2011;42(9).pp.2385-6.

Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290(2):F262-F272.

Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996;97(10):2167-73.

Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor- related protein (LRP) in chronic renal failure. Kidney Int. 2005;67(3):1028-32.

Mozos I, Caraba A. Electrocardiographic predictors of Cardiovascular mortality. Disease markers. 2015:1-10.

Shafi S, Saleem M, Anjum R, Abdullah W, Shafi T. ECG abnormalities in patients with chronic kidney disease. J Ayub Med Coll Abbottabad. 2017;29(1):61-4.